A new publication involving copper tripeptide-1, also known as GHK-Cu, appeared on May 10, 2026. The paper is titled "Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO4 or LPS induced-inflammation in Zebrafish larvae model." It was published in the European Journal of Pharmacology.
The study is listed under PubMed ID 41997403. Copper tripeptide-1 is currently categorized as an approved compound. This entry marks the publication event only, based on the title and journal information provided.
No specific findings, outcomes, or data points from the study are detailed here beyond the publication itself. Readers interested in the full scope of the research should consult the original source. For general background on this compound, readers can refer to the compound overview.</body_markdown>
<parameter name="sources">["https://pubmed.ncbi.nlm.nih.gov/41997403/"]